- Previous Close
155.17 - Open
155.17 - Bid 156.46 x 1000
- Ask 156.48 x 900
- Day's Range
155.14 - 157.01 - 52 Week Range
143.13 - 168.85 - Volume
1,620,881 - Avg. Volume
6,418,146 - Market Cap (intraday)
376.72B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
25.86 - EPS (TTM)
6.05 - Earnings Date Jan 22, 2025
- Forward Dividend & Yield 4.96 (3.20%)
- Ex-Dividend Date Nov 26, 2024
- 1y Target Est
174.89
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
www.jnj.com131,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: JNJ
View MorePerformance Overview: JNJ
Trailing total returns as of 11/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JNJ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JNJ
View MoreValuation Measures
Market Cap
373.59B
Enterprise Value
389.04B
Trailing P/E
25.65
Forward P/E
14.51
PEG Ratio (5yr expected)
0.92
Price/Sales (ttm)
4.30
Price/Book (mrq)
5.32
Enterprise Value/Revenue
4.44
Enterprise Value/EBITDA
15.15
Financial Highlights
Profitability and Income Statement
Profit Margin
16.74%
Return on Assets (ttm)
8.40%
Return on Equity (ttm)
20.89%
Revenue (ttm)
87.7B
Net Income Avi to Common (ttm)
14.77B
Diluted EPS (ttm)
6.05
Balance Sheet and Cash Flow
Total Cash (mrq)
20.3B
Total Debt/Equity (mrq)
50.96%
Levered Free Cash Flow (ttm)
19.92B